A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Jun 2018
At a glance
- Drugs Acalabrutinib (Primary) ; Vistusertib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Proof of concept
- Sponsors Acerta Pharma
- 31 May 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Dec 2017 Data from this trial will be presented at the 59th 2017 American Society of Hematology (ASH) Annual Meeting & Exhibition, according to an AstraZeneca media release.
- 04 Jul 2017 New trial record